As Biotechnology businesses, Otonomy Inc. (NASDAQ:OTIC) and Intec Pharma Ltd. (NASDAQ:NTEC), are affected by contrast. This especially applies to their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.
Table 1 shows the gross revenue, earnings per share and valuation for Otonomy Inc. and Intec Pharma Ltd.
Table 2 represents Otonomy Inc. (NASDAQ:OTIC) and Intec Pharma Ltd. (NASDAQ:NTEC)’s return on assets, net margins and return on equity.
In next table is given Otonomy Inc. and Intec Pharma Ltd.’s ratings and recommendations.
Otonomy Inc.’s upside potential is 86.57% at a $5 consensus price target.
Insider Institutional Ownership
The shares of both Otonomy Inc. and Intec Pharma Ltd. are owned by institutional investors at 66.1% and 39.64% respectively. About 0.29% of Otonomy Inc.’s share are owned by insiders. Competitively, 11.81% are Intec